CN BIO INNOVATIONS
CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip® platform. The HBV disease model, which is referred to as Quantum-B... ®, is currently being deployed in drug discovery and research alliances with a number of leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next generation organ-on-chips which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market.
CN BIO INNOVATIONS
Industry:
Biopharma Biotechnology Health Care Life Science Medical Medical Device
Founded:
2009-01-01
Address:
Welwyn Garden City, Hertford, United Kingdom
Country:
United Kingdom
Website Url:
http://www.cn-bio.com
Total Employee:
11+
Status:
Active
Contact:
44 18 6530 9600
Total Funding:
23.53 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag
Similar Organizations
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Current Advisors List
Advisor
Current Employees Featured
Maureen Coleman Executive Chairman @ CN Bio Innovations
Executive Chairman
2020-04-01
Maureen Coleman Chairman @ CN Bio Innovations
Chairman
2010-04-01
Jill Urban Co-Founder @ CN Bio Innovations
Co-Founder
Linda Griffith Co-Founder @ CN Bio Innovations
Co-Founder
David Hughes CEO @ CN Bio Innovations
CEO
2018-07-01
Patrick Driscoll Chief Financial Officer @ CN Bio Innovations
Chief Financial Officer
2019-01-01
Founder
Investors List
GrayBella Capital
GrayBella Capital investment in Series B - CN Bio Innovations
Innovate UK
Innovate UK investment in Grant - CN Bio Innovations
CN Innovations
CN Innovations investment in Venture Round - CN Bio Innovations
CITIC Securities
CITIC Securities investment in Venture Round - CN Bio Innovations
Innovate UK
Innovate UK investment in Grant - CN Bio Innovations
CN Innovations
CN Innovations investment in Seed Round - CN Bio Innovations
Official Site Inspections
http://www.cn-bio.com Semrush global rank: 4.54 M Semrush visits lastest month: 2.32 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "CN Bio Innovations"
CN Bio | Organ-on-a-chip company | Human Drug Discovery
CN Bio and Pharmaron establish long-term strategic partnership to develop OOC technologies on a global R&D platform April 24, 2025; FDA’s plan to phase out animal testing requirement for …See details»
CN Bio - Crunchbase Company Profile & Funding
CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip …See details»
CN Bio | Drug Discovery News
Mar 26, 2025 CN Bio CN Bio is a leading organ-on-a-chip (OOC) company based in Cambridge, UK. CN Bio offers a portfolio of products and services to optimise the accuracy and efficiency …See details»
Leadership team - CN Bio
Deepak Singh joins CN Bio Innovations in February 2023. He has over 30 years of commercial experience within the life science industry, leading high-performance sales, support & …See details»
CN Bio - Lab Manager
Feb 10, 2025 CN Bio CN Bio develops organ-on-a-chip technologies that mimic human physiology for drug discovery and development. Their cutting-edge platforms accelerate the …See details»
CN Bio Innovations - The Org
CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. Industries. Biotechnology, Health Care + 2. …See details»
CN Bio Org Chart + Executive Team - The Official Board
The organizational chart of CN Bio displays its 11 main executives including Paul Brooks, Deepak Singh and Joe Parisi Toggle navigation The Official Board SearchSee details»
CN Bio Company Profile - Office Locations, Competitors, Revenue …
CN Bio has 5 employees across 2 locations, $11.51 m in total funding, and £2.13 m in annual revenue in FY 2022. See insights on CN Bio including office locations, competitors, revenue, …See details»
CN-Bio 2025 Company Profile: Valuation, Funding
CN-Bio General Information Description. Manufacturer of a microphysiological system intended for advancing biomedical research and drug development. The company's device replicates the microenvironment of human organs and …See details»
CN Bio Profile | The Scientist
Mar 18, 2021 Content provided by CN Bio. Harnessing the capabilities of the PhysioMimix Multi-organ System, the kit enhances lead optimization and preclinical testing pipelines, providing …See details»
CN Bio - businessweekly.co.uk
Jan 27, 2025 CN Bio is an organ-on-a-chip (OOC) company that accelerates and economises drug discovery using predictive human organ models. Courtesy – CN Bio The company’s …See details»
CN Bio Innovations - Human Relevant Science
CN Bio is also developing organ-on-chip models for specific diseases including non-alcoholic steatohepatitis and Hepatitis B. CN Bio is a co-recipient with MIT of a $26M US Federal …See details»
CN Bio raises $21 million; the OOC company will fund global …
Apr 23, 2024 Charles Chong, Managing Director, CN Innovations, added: “We are encouraged by CN Bio’s ongoing success and, in particular, the team’s achievements over the past years, …See details»
CN Bio Information - RocketReach
CN Bio is a leading organ-on-a-chip (OOC) company that enables researchers to improve the accuracy and efficiency of preclinical drug discovery. Our PhysioMimix® suite of …See details»
CN Bio and Pharmaron Establish Long-Term Strategic
5 days ago CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic …See details»
CN Bio raises $21 million USD in first close of Series B ... - OBN
Apr 29, 2024 Dr Paul Brooks, CEO, CN Bio • Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively• Investment will expand …See details»
CN Bio raises $21 million USD in first close of Series B investment ...
Apr 23, 2024 Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively Investment will expand product development and scaling of the …See details»
CN Bio and Pharmaron Establish Long-Term Strategic Partnership …
4 days ago Dr Paul Brooks, CEO, CN Bio, said: “Pharmaron is a global, premier and trusted service provider for the life sciences industry. As such, Pharmaron were the ideal partner for …See details»
Events | Find out where will we be next! - CN Bio
Jun 10, 2024 ©2024 CN Bio Innovations Ltd Registered No. 06517359. VAT No. GB978184563. Latest news. CN Bio and Pharmaron establish long-term strategic partnership to develop OOC …See details»
CN Bio raises $21 million USD in first close of Series B investment …
Apr 23, 2024 Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10 M and $5.5 M, respectively. Investment will expand product development and scaling of …See details»